Sodium, hypertension, and an explanation of the "lag phenomenon" in hemodialysis patients

Hemodialysis International

Volumn 12, Issue 4, 2008, Pages 412-425

  Twardowski, Zbylut J ^a,b  

^a University of Missouri   (United States)

^b Dialysis Clinic Incorporated   (United States)

Author keywords

Blood pressure; Intracellular sodium; Lag phenomenon; Nitric oxide; Peripheral resistance; Sodium homeostasis

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCIUM; NATRIURETIC FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OUABAIN; POTASSIUM; SODIUM; THIAZIDE DIURETIC AGENT; WATER;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BLOOD VOLUME; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; CHRONIC KIDNEY DISEASE; DRY WEIGHT; ETHNIC DIFFERENCE; EXTRACELLULAR SPACE; GLOMERULUS FILTRATION RATE; HEART OUTPUT; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPERALDOSTERONISM; HYPERTENSION; LACTATION; LAG PHENOMENON; LONGEVITY; NATRIURESIS; NONHUMAN; PLASMA RENIN ACTIVITY; PREGNANT WOMAN; PREVALENCE; SALT INTAKE; SODIUM BALANCE; SODIUM EXCRETION; SODIUM RESTRICTION; SODIUM URINE LEVEL; VASCULAR RESISTANCE; VASOCONSTRICTION;

ANIMALS; HOMEOSTASIS; HUMANS; HYPERTENSION, RENAL; KIDNEY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; SODIUM CHLORIDE, DIETARY;

EID: 53649084367     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00304.x     Document Type: Article

References (104)

1. MacGregor GA, de Wardener HE. Salt, Diet & Health, Neptune's Poisoned Chalice: The Origins of High Blood Pressure. Cambridge, UK: Cambridge University Press; 1998.
2. Tekol Y. Salt addiction: A different kind of drug addiction. Med Hypotheses. 2006; 67: 1233-1234.
3. Huang Ti Nei Ching Su Wên. The Yellow Emperor's Classic of Internal Medicine. Translated by Veith I. Berkeley, CA: University of California Press; 1966: 141.
4. Ambard L, Beaujard E. Causes de l'hypetension artérielle (Causes of arterial hypertension). Arch Gén Méd S.H. 1904; 1: 520-532.
5. Ambard L, Beaujard E. La rétension chlorurée sèche (Dry chloride retension). Sem Med, Par. 1905; XXV: 133-136.
6. Ambard L. L'origine rénale de l'hypertension artérièlle permanente (Renal origin of permanent arterial hypertension). Sem Med, Par. 1906; XXVI: 361-366.
7. Combe A. Beiträge zur Kenntnis der chlor-und stickstoffarmen Ernährung bei Morbus Brightii (Comments on the diet low in chloride and nitrogen in Morbus Brightii). Monatsschr Kinderh Leipz Wien. 1905; iv: 13-82.
8. Laufer RJ. La tension artérielle et la pathogénie de l'oedème - La régime hydrique et hypochlorurédans les néphrites (Arterial pressure and pathogenesis of edema - diet containing variable volume of water and low chloride in nephritides). C R Soc Biol. 1904; LVI: 249-251.
9. Allen FM. Arterial hypertension. JAMA. 1920; 74: 652-655.
10. Allen FM, Sherill JW. The treatment of arterial hypertension. J Metabol Res. 1922; ii: 429-545.
11. Houghton HA. The treatment of arterial hypertension with low sodium chloride dietary. Med Rec. 1922; CI: 441-446.
12. Kempner W. Treatment of kidney disease and hypertensive vascular disease with rice diet. NC Med J. 1944; 5: 125-133.
13. Grollman A, Harrison TR. Effect of rigid sodium restriction on blood pressure and survival of hypertensive rats. Proc Soc Exp Biol Med. 1945; 60: 52-55.
14. Grollman A, Harrison TR, Mason MF, Baxter J, Crampton J, Reichsman F. Sodium restriction in the diet for hypertension. JAMA. 1945; 129: 533-537.
15. Kempner W. Treatment of hypertensive vascular disease with rice diet. Am J Med. 1948; 4: 545-577. Reprinted in Arch Intern Med. 1974; 133: 758-790.
16. Dole VP, Dahl LK, Cotzias GC, Eder HA, Krebs ME. Dietary treatment of hypertension. Clinical and metabolic studies of patients on the rice-fruit diet. J Clin Invest. 1950; 29: 1189-1206.
17. Dole VP, Dahl LK, Cotzias GC, Dziewiatkowski DD, Harris C. Dietary treatment of hypertension. II. Sodium depletion as related to the therapeutic effect. J Clin Invest. 1951; 30: 584-595.
18. Dole VP, Dahl LK, Schwartz IL, Cotzias GC, Thaysen JH, Harris C. Dietary treatment of hypertension. III. The effect of protein on appetite and weight. J Clin Invest. 1953; 32: 185-191.
19. Kempner W. Treatment of heart and kidney disease and of hypertensive and arteriosclerotic vascular disease with the rice diet. Ann Intern Med. 1949; 31: 821-856.
20. Murphy RJF. The effect of "rice diet" on plasma volume and extracellular fluid space in hypertensive subjects. J Clin Invest. 1950; 29: 912-917.
21. Dahl LK. Salt intake and salt need. N Engl J Med. 1958; 258: 1152-1157 (contd).
22. Dahl LK. Salt intake and salt need. N Engl J Med. 1958; 258: 1205-1208 (concl).
23. Meneely GR, Dahl LK. Electrolytes in hypertension: The effects of sodium chloride. The evidence from animal and human studies. Med Clin North Am. 1961; 45: 271-283.
24. Dahl LK. Salt and hypertension. Am J Clin Nutr. 1972; 25: 231-244.
25. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium related hormones in the Yanomamo Indians, a "no-salt" culture. Circulation. 1975; 52: 146-151.
26. Oliver WJ, Neel JV, Grekin RJ, Cohen EL. Hormonal adaptation to the stress imposed upon sodium balance by pregnancy and lactation in the Yanomama Indians, a culture without salt. Circulation. 1981; 63: 110-116.
27. Sasaki N. High blood pressure and salt intake of the Japanese. Jpn Heart J. 1962; 3: 313-324.
28. Intersalt Cooperative Research Group. Intersalt: An international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ. 1988; 297: 319-328.
29. Elliott P. Observational studies of salt and blood pressure. Hypertension. 1991; 17 (Suppl 1): 1-3-1-8.
30. Stamler J, Rose G, Elliott P, et al. Findings of the International Cooperative INTERSALT Study. Hypertension. 1991; 17(Suppl 1): 1-10-1-15.
31. Stamler R. Implications of the INTERSALT Study. Hypertension. 1991; 17(Suppl 1): 1-16-1-20.
32. Kaplan NM. Dietary salt intake and blood pressure. JAMA. 1984; 251: 1429-1430.
33. Wilson TW, Grim CE. Biohistory of slavery and blood pressure differences in blacks today. A hypothesis. Hypertension. 1991; 17(Suppl 1): i-122-i-128.
34. Kaufman JS, Hall SA. The slavery hypertension hypothesis: Dissemination and appeal of a modern race theory. Epidemiology. 2003; 14: 111-117.
35. Ball CO, Meneely GR. Observations on dietary sodium chloride. J Am Diet Assoc. 1957; 33: 366-370.
36. Dahl LK. Salt and hypertension. Am J Clin Nutr. 1972; 25: 231-244.
37. Eichberg JW, Shade RE. "Normal" blood pressure in chimpanzees. J Med Primatol. 1987; 16: 317-321.
38. Denton D, Weisinger R, Mundy NI, et al. The effect of increased salt intake on blood pressure of chimpanzees. Nat Med. 1995; 1: 1009-1016.
39. Karppanen H, Mervaala E. Sodium intake and hypertension. Prog Cardiovasc Dis. 2006; 49: 59-75.
40. Guyton AC. Kidneys and fluids in pressure regulation. Small volume but large pressure changes. Hypertension. 1992; 19(Suppl 1): I2-I8.
41. Conway J, Lauwers P. Hemodynamic and hypertensive effects of long-term therapy with chlorothiazide. Circulation. 1960; XXI: 21-27.
42. Kaplan NM. Clinical Hypertension. 6th ed. Baltimore, MD: William & Wilkins; 1994: 200.
43. Conway J. Hemodynamic consequences of induced changes in blood volume. Circ Res. 1966; XVIII: 190-198.
44. Chen WT, Brace RA, Scott JB, Anderson DK, Haddy FJ. The mechanism of the vasodilator action of potassium. Proc Soc Exp Biol Med. 1972; 140: 820-824.
45. Haddy FJ, Overbeck HW. The role of humoral agents in volume expanded hypertension. Life Sci. 1976; 19: 935-947.
46. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: A reassessment and a hypothesis. Am J Physiol. 1977; 232: C165-C173.
47. 2+ stores and cell responsiveness. Am J Physiol Cell Physiol. 1993; 264: C1367-C1387.
48. Haddy FJ, Pamnani MB. Role of dietary salt in hypertension. J Am Coll Nutr. 1995; 14: 428-438.
49. Haddy FJ. Role of dietary salt in hypertension. Life Sci. 2006; 79: 1585-1592.
50. Blaustein MP, Zhang J, Chen L, Hamilton BP. How does salt retention raise blood pressure? Am J Physiol Regul Integr Comp Physiol. 2006; 290: R514-R523.
51. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology. 1993; 132: 1961-1970.
52. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 1992; 92: 29-34.
53. Houben AJ, van der Zander K, de Leeuw PW. Vascular and renal actions of brain natriuretic peptide in man: Physiology and pharmacology. Fundam Clin Pharmacol. 2005; 19: 411-419.
54. Dastoor H, Bernieh B, Boobes Y, et al. Plasma BNP in patients on maintenance haemodialysis. J Hypertens. 2005; 23: 23-28.
55. Odar-Cederlöf I, Bjellerup P, Williams A, et al. Plasma levels of brain natriuretic peptide (BNP) decrease in daily dialysis, suggesting improved left ventricular function. Hemodial Int. 2006; 10: 394-398.
56. Campese VM, Mozayeni P, Ye S, Gumbard M. High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol. 2002; 15: 407-413.
57. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004; 24: 354-365.
58. Shapiro L, Dinarello CA. Hyperosmotic stress as a stimulant for proinflammatory cytokine production. Exp Cell Res. 1997; 231: 354-362.
59. Dihazi H, Kessler R, Eschrich K. High osmolarity glycerol (HOG) pathway-induced phosphorylation and activation of 6-phosphofructo-2-kinase are essential for glycerol accumulation and yeast cell proliferation under hyperosmotic stress. J Biol Chem. 2004; 279: 23961-23968.
60. Shapiro L, Dinarello CA. Osmotic regulation of cytokine synthesis in vitro. Proc Natl Acad Sci USA. 1995; 92: 12230-12234.
61. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003; 23: 1455-1459.
62. Khosla UM, Johnson RJ. Hypertension in the hemodialysis patient and the "lag phenomenon": Insights into pathophysiology and clinical management. Am J Kidney Dis. 2004; 43: 739-751.
63. Tojo A, Kimoto M, Wilcox CS. Renal expression of constitutive NOS and DDAH: Separate effects of salt intake and angiotensin. Kidney Int. 2000; 58: 2075-2083.
64. Edelman IS, Leibman J. Anatomy of body water and electrolytes. Am J Med. 1959; 27: 256-277.
65. Garnett ES, Ford J, Golding PL, Mardell RJ, Whyman AE. The mobilization of osmotically inactive sodium during total starvation in man. Clin Sci. 1968; 35: 93-103.
66. Titze J, Maillet A, Lang R, et al. Long-term sodium balance in humans in a terrestrial space station simulation study. Am J Kidney Dis. 2002; 40: 508-516.
67. + storage in the skin. Am J Physiol Heart Circ Physiol. 2004; 287: H203-H208.
68. Gerzer R, Heer M. Regulation of body fluid and salt homeostasis - from observations in space to new concepts on Earth. Curr Pharm Biotechnol. 2005; 6: 299-304.
69. Uribarri J, Oh MS, Carroll HJ. Salt-losing nephropathy. Clinical presentation and mechanisms. Am J Nephrol. 1983; 3: 193-198.
70. Fulop M. A patient with sodium- and potassium-losing nephropathy. Am J Med Sci. 2003; 325: 93-97.
71. Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol. 2006; 104: 73-80.
72. Tobe SW, Burgess E, Lebel M. Atherosclerotic renovascular disease. Can J Cardiol. 2006; 22: 623-628.
73. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens. 1988; 1(4 Pt 1): 335-347.
74. Strojek K, Nicod J, Ferrari P, et al. Salt-sensitive blood pressure - An intermediate phenotype predisposing to diabetic nephropathy? Nephrol Dial Transplant. 2005; 20: 2113-2119.
75. Koomans HA, Roos JC, Boer P, Geyskes GG, Dorhout Mees EJ. Salt sensitivity of blood pressure in chronic renal failure: Evidence for renal control of body fluid distribution in man. Hypertension. 1982; 4: 190-197.
76. Scribner BH. Bedside determination of chloride: A method for plasma, urine, and other fluids and its application to fluid balance problems. Proc Staff Meeting Mayo Clinic. 1950; 25: 209-218.
77. Scribner BH, Buri R, Caner JEZ, Hegstrom R, Burnell JM. The treatment of chronic uremia by means of intermittent hemodialysis: A preliminary report. Trans Am Soc. Artif Intern Organs. 1960; 6: 114-122. Reprinted in J Am Soc Nephrol. 1998; 9: 719-726.
78. Scribner BH. A personalized history of chronic hemodialysis. Am J Kidney Dis. 1990; 16: 511-519.
79. Thomson GE, Waterhouse K, McDonald HP Jr., Friedman EA. Hemodialysis for chronic renal failure. Clinical observations. Arch Intern Med. 1967; 120: 153-167.
80. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med. 1969; 280: 978-981.
81. Pendras JP, Erickson RV. Hemodialysis: A successful therapy for chronic uremia. Ann Intern Med. 1966; 64: 293-311.
82. Craswell PW, Hird VM, Judd PA, Baillod RA, Varghese Z, Moorhead JF. Plasma renin activity and blood pressure in 89 patients receiving maintenance haemodialysis therapy. Br Med J. 1972; 4: 749-753.
83. Twardowski Z. Effect of long-term increase in the frequency and/or prolongation of dialysis duration on certain clinical manifestations and results of laboratory investigations in patients with chronic renal failure. Acta Med Pol. 1975; 16: 31-44. Republished in the section: Historical Milestones in Daily Dialysis. Hemodial Int. 2004; 8: 30-38.
84. Schupak E, Merrill JP. Experience with long-term intermittent hemodialysis. Ann Intern Med. 1965; 62: 509-518.
85. Sellars L, Robson V, Wilkinson R. Sodium retention and hypertension with short dialysis. Br Med J. 1979; 1: 520-521.
86. Wizemann V, Kramer W. Short-term dialysis-long-term complications. Ten years' experience with short-duration renal replacement therapy. Blood Purif. 1987; 5: 193-201.
87. Twardowski ZJ. Short, thrice-weekly hemodialysis is inadequate regardless of small molecule clearance. Int J Artif Organs. 2004; 27: 452-466.
88. Henderson LW. Symptomatic hypotension during hemodialysis. Kidney Int. 1980; 17: 571-576.
89. Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: An overview. J Am Soc Nephrol. 1999; 10: 392-403.
90. Lopot F, Nejedly B, SulkováS. Continuous blood pressure monitoring and ultrafiltration. Hemodial Int. 2000; 4: 8-14.
91. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK. HEMO Study Group. Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO study. Am J Nephrol. 2001; 21: 280-288.
92. Charra B, Bergström J, Scribner BH. Blood pressure control in dialysis patients: Importance of the lag phenomenon. Am J Kidney Dis. 1998; 32: 720-724.
93. Charra B, Jean G, Hurot J-M, et al. Clinical determination of dry body weight. Hemodial Int. 2001; 5: 42-50.
94. Covic A, Goldsmith DJ, Venning MC, Ackrill P. Long-hours home haemodialysis - The best renal replacement therapy method? Q J Med. 1999; 92: 251-260.
95. McGregor DO, Buttimore AL, Nicholls MG, Lynn KL. Ambulatory blood pressure monitoring in patients receiving long, slow home hemodialysis. Nephrol Dial Transplant. 1999; 14: 2676-2679.
96. Özkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant. 1998; 13: 1489-1493.
97. Özkahya M, Ok E, Töz H, et al. Long-term survival rates in haemodialysis patients treated with strict volume control. Nephrol Dial Transplant. 2006; 21: 3506-3513.
98. Franz M, Pohanka E, Tribl B, Woloszczuk W, Hörl WH. Living on chronic hemodialysis between dryness and fluid overload. Kidney Int Suppl. 1997; 9: S39-S42.
99. Wizemann V, Schilling M. Dilemma of assessing volume state - The use and limitations of a clinical score. Nephrol Dial Transplant. 1995; 10: 2114-2117.
100. Scribner BH. Discussion. Trans Am Soc Artif Intern Organs. 1962; 8: 298.
101. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet. 1967; 2: 69-73.
102. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffman K-H, Ritz E. Concentration of dimethyl-l-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant. 1996; 11: 2449-2452.
103. Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999; 10: 594-600.
104. Shaldon S. An explanation for the "lag phenomenon" in drug-free control of hypertension by dietary salt restriction in patients with chronic kidney disease on hemodialysis. Clin Nephrol. 2006; 66: 1-2.